Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 318

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 318
---
; NASDAQ: CRDF). Dr. Sheinerman received her Ph.D. in Biomedical Sciences from Mount Sinai School
of Medicine for her work on molecular mechanisms of Alzheimer’s Disease. Dr. Sheinerman also holds an Honors MBA from the
Zicklin School of Business, Baruch College/CUNY.

Gary Anthony, Chief Financial Officer. Gary Anthony is an independent consultant providing management and support services to
pre-IPO and smaller reporting public companies with respect to accounting, financial reporting, and internal controls. Since November
2022, Mr. Anthony has served the Company as a financial consultant and Acting Chief Financial Officer. Since 2022, Mr. Anthony has
primarily provided interim controller and financial reporting services to various such companies in pharmaceutical, software, manufacturing,
and service industries. From 2020 to 2022 he served as Controller of IPKeys Power Partners and from 2019 to 2020 Controller of Heat Biologics.
Previously, he served as Chief Financial Officer of Algos Pharmaceutical Corporation and Axion International and principal accounting
officer of Majesco Entertainment and Xenomics. Mr. Anthony earned his BS in Accounting from Monmouth College and initially
served on the audit staff of Coopers & Lybrand.

<div align='center'>170</div>

Significant Employees

The following are employees who are not executive officers, but who are expected to make significant contributions to Diamir’s business:

Gyanendra Kumar, PhD, VP, Assay Development.
Dr. Kumar joined DiamiR in April 2021, and is an accomplished research & development leader, with experience in leading CLIA facility
operations. Dr. Kumar has 20+ years of experience in the development of technologies for molecular diagnostic and other applications.
Prior to joining DiamiR, he was VP of Assay Development at Interpace Biosciences. From 2014 to 2021, he led the completion of product
development, validation, and launch of two molecular diagnostic tests for thyroid malignancy based upon Next Generation Sequencing and
microRNA profiling. From 1999 to 2009, Dr. Kumar led R&D efforts for the development of whole genome amplification (WGA) technologies
at Molecular Staging and at GE Healthcare. Furthermore, he has expertise and record of establishing independent research programs related
to “Expression Regulation and Functional Genomics”. Prior to joining biotechnology industry, Dr. Kumar was Associate Professor
of Molecular Biology & Genetics (1988-1996